Authorized purpose: Provide predefined cardiovascular images and measurements to support pre-procedural planning for patients with aortic stenosis being considered for TAVR; cardiologists and radiologists must interpret and validate the report and make all treatment decisions.
Clinical role
Off-site semi-automatic post-processing and measurement: clinical users upload CTA, DASI operators process and quality-check the report, and cardiologists or radiologists interpret and validate the released measurements.
Images and patients
CT/CTA · Cardiovascular structures (aortic root, aortic valve, sinus of Valsalva, sinotubular junction, and ascending aorta)
Key limitation
Keep in mind: Not diagnostic and does not determine recommended medical care; clinicians retain responsibility for interpretation, validation, and treatment decisions. Control-point error greater than 3 mm can materially affect final measurements, and the FDA performance evidence includes a 40-case performance validation, a 14-CTA operator-variability study, and no prospective clinical trial. Off-site processing, operator input, and local portal/data-governance requirements require separate qualification.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provide predefined cardiovascular images and measurements to support pre-procedural planning for patients with aortic stenosis being considered for TAVR; cardiologists and radiologists must interpret and validate the report and make all treatment decisions.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Cardiovascular structures (aortic root, aortic valve, sinus of Valsalva, sinotubular junction, and ascending aorta) Input: Patient multiphase DICOM computed tomography angiography chest image files from patients with tricuspid aortic valves and aortic stenosis being considered for TAVR, uploaded through the DASI Simulations web portal.
Who uses it?Intended users: Cardiologists and radiologists receive and interpret the results; trained DASI Simulations operators perform the processing workflow and quality checks, and the software is not operated directly by physicians.
What does the software produce?Output: A viewable and downloadable report with predefined images and diameters, lengths, angles, areas, and perimeters for pre-TAVR cardiovascular structures, including aortic annulus, sinus of Valsalva, sinotubular junction, ascending aorta, and aortic valve angle.
What is its most important limitation?Key limitation: Not diagnostic and does not determine recommended medical care; clinicians retain responsibility for interpretation, validation, and treatment decisions. Control-point error greater than 3 mm can materially affect final measurements, and the FDA performance evidence includes a 40-case performance validation, a 14-CTA operator-variability study, and no prospective clinical trial. Off-site processing, operator input, and local portal/data-governance requirements require separate qualification.
Clinical takeaway. Clinical role: Provide predefined cardiovascular images and measurements to support pre-procedural planning for patients with aortic stenosis being considered for TAVR; cardiologists and radiologists must interpret and validate the report and make all treatment decisions.
Evidence takeaway. Evidence from the reviewed source record: FDA K231324 reports software verification, non-clinical bench testing, control-point validation, automatic-measurement validation, performance validation, operator-variability, human-factors, and control-point-sensitivity studies. The performance-validation cohort contained 40 CTA patients with tricuspid aortic valves and aortic stenosis: control-point success was 85.3%, mean annulus-area error was 0.93%, annulus-perimeter error was -1.02%, and aortic-valve-angle difference was 2.66%. An operator study using 14 CTAs and five operators reported ICC 0.96. No prospective clinical trials were conducted.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provide predefined cardiovascular images and measurements to support pre-procedural planning for patients with aortic stenosis being considered for TAVR; cardiologists and radiologists must interpret and validate the report and make all treatment decisions.
Off-site semi-automatic post-processing and measurement: clinical users upload CTA, DASI operators process and quality-check the report, and cardiologists or radiologists interpret and validate the released measurements.
Patient multiphase DICOM computed tomography angiography chest image files from patients with tricuspid aortic valves and aortic stenosis being considered for TAVR, uploaded through the DASI Simulations web portal.
A viewable and downloadable report with predefined images and diameters, lengths, angles, areas, and perimeters for pre-TAVR cardiovascular structures, including aortic annulus, sinus of Valsalva, sinotubular junction, ascending aorta, and aortic valve angle.
Cardiologists and radiologists receive and interpret the results; trained DASI Simulations operators perform the processing workflow and quality checks, and the software is not operated directly by physicians.
Not diagnostic and does not determine recommended medical care; clinicians retain responsibility for interpretation, validation, and treatment decisions. Control-point error greater than 3 mm can materially affect final measurements, and the FDA performance evidence includes a 40-case performance validation, a 14-CTA operator-variability study, and no prospective clinical trial. Off-site processing, operator input, and local portal/data-governance requirements require separate qualification.
FDA K231324 reports software verification, non-clinical bench testing, control-point validation, automatic-measurement validation, performance validation, operator-variability, human-factors, and control-point-sensitivity studies. The performance-validation cohort contained 40 CTA patients with tricuspid aortic valves and aortic stenosis: control-point success was 85.3%, mean annulus-area error was 0.93%, annulus-perimeter error was -1.02%, and aortic-valve-angle difference was 2.66%. An operator study using 14 CTAs and five operators reported ICC 0.96. No prospective clinical trials were conducted.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K231324 reports software verification, non-clinical bench testing, control-point validation, automatic-measurement validation, performance validation, operator-variability, human-factors, and control-point-sensitivity studies. The performance-validation cohort contained 40 CTA patients with tricuspid aortic valves and aortic stenosis: control-point success was 85.3%, mean annulus-area error was 0.93%, annulus-perimeter error was -1.02%, and aortic-valve-angle difference was 2.66%. An operator study using 14 CTAs and five operators reported ICC 0.96. No prospective clinical trials were conducted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
DASI Dimensions (V1.0) regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231324
IndependenceIndependence not established
K231324
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231324. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Patient multiphase DICOM computed tomography angiography chest image files from patients with tricuspid aortic valves and aortic stenosis being considered for TAVR, uploaded through the DASI Simulations web portal.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Off-site DASI Simulations web portal accepts uploaded patient multiphase DICOM CTA files and returns a digital report for viewing or download. The FDA summary describes trained operators and secure AWS data collection for testing, but that vendor/test infrastructure does not establish a current production deployment, PACS/RIS/EHR interface, or local compatibility.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes DASI Dimensions as an off-site software system that receives multiphase DICOM CTA uploads through the DASI Simulations web portal, with the processed report released to the end user via the portal for viewing and downloading. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "DASI Dimensions is an off-site software syst em that receives cardiologists and/or radio log ists' input via upload of pat ient multiphase DICOM computed tomography angiography (CTA) chest image files through DASI Simulations web portal." … "The processed report is then available for viewing and downloading.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: A viewable and downloadable report with predefined images and diameters, lengths, angles, areas, and perimeters for pre-TAVR cardiovascular structures, including aortic annulus, sinus of Valsalva, sinotubular junction, ascending aorta, and aortic valve angle.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A viewable and downloadable report with predefined images and diameters, lengths, angles, areas, and perimeters for pre-TAVR cardiovascular structures, including aortic annulus, sinus of Valsalva, sinotubular junction, ascending aorta, and aortic valve angle.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes DASI Dimensions as an off-site software system that receives multiphase DICOM CTA uploads through the DASI Simulations web portal, with the processed report released to the end user via the portal for viewing and downloading. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DASI Dimensions is an off-site software syst em that receives cardiologists and/or radio log ists' input via upload of pat ient multiphase DICOM computed tomography angiography (CTA) chest image files through DASI Simulations web portal." … "The processed report is then available for viewing and downloading.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Off-site DASI Simulations web portal accepts uploaded patient multiphase DICOM CTA files and returns a digital report for viewing or download. The FDA summary describes trained operators and secure AWS data collection for testing, but that vendor/test infrastructure does not establish a current production deployment, PACS/RIS/EHR interface, or local compatibility.
ACR AI Central provides an exact-submission model card for DASI Dimensions (V1.0); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K231324 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.
Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.